A Novel CA4P Polymeric Nanoparticle for Murine Hepatoma Therapy  

作　　者：Zhi-Lin Liu Xi-Tong Ren Yue Huang Jia-Li Sun Xiao-Shuang Wang Meng-Fei Zheng Lin-Jie Cui Xue-Fei Zhang Zhao-Hui Tang 

机构地区：[1]Key Laboratory of Polymer Ecomaterials,Changchun Institute of Applied Chemistry,Chinese Academy of Sciences,Changchun 130022,China [2]Jilin Biomedical Polymers Engineering Laboratory,Changchun 130022,China [3]School of Applied Chemistry and Engineering,University of Science and Technology of China,Hefei 230026,China [4]No.1 Department of Neurology,China-Japan Union Hospital of Jilin University,Changchun 130033,China [5]Key Laboratory of Environmentally Friendly Chemistry and Applications of Ministry of Education and Key Laboratory of Polymeric Materials&Application Technology of Hunan Province,College of Chemistry,Xiangtan University,Xiangtan 411105,China

出　　处：《Chinese Journal of Polymer Science》2023年第8期1223-1229,I0007,共8页高分子科学（英文版）

基　　金：financially supported by the Ministry of Science and Technology of China(No.2022YFE0110200);the Natural Science Foundation of Hunan Province of China(No.2021JJ30680);the National Natural Science Foundation of China(Nos.52203198,52025035 and 52103195)。

摘　　要：Combretastatin A4 phosphate(CA4P)is a potent vascular disrupting agent with good water solubility.However,it is only effective at high doses,which decreases clinical applicability.Herein,we designed stable CA4P polymeric nanoparticles(CA4P NPs)consisting of various cholesterol derivatives,and with a drug loading efficacy of 93%.The nanoparticles released CA4P in a sustained manner and achieved a 72%inhibition rate in the murine H22 liver tumor model,which was about 2.9-fold higher than that of free CA4P(24.6%).Furthermore,the carrier components of CA4P NPs were metabolized to arginine,cholesterol,ethanol and poly(ethylene glycol)in vivo;therefore,the CA4P NPs are safe and have significant potential for clinical translation.

关 键 词：CA4P polymeric nanoparticle Cholesterol derivatives Vascular disrupting agent Phosphate-guanidine coordination Drug controlled release 

分 类 号：R730[医药卫生—肿瘤] TB383.1[医药卫生—临床医学]